Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-07-07
1997-08-26
Wax, Robert A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
435 681, 435 691, 530413, A61K 3817, A61K 3818, C07K 112
Patent
active
056611269
ABSTRACT:
This application concerns the treatment of certain tumors using an effective amount of the glycoprotein Mullerian Inhibiting Substance (MIS). This application further concerns the treatment of certain tumors using an effective amount of the C-terminal fragment of MIS. Also, this application concerns DNA sequences encoding the C-terminal fragment of MIS, vectors containing the DNA sequence and transformed host cells capable of producing the C-terminal fragment. This application further concerns treating certain tumors by transfecting tumor cells with a gene coding for MIS or the C-terminal fragment of MIS. Gene therapy treatments for inhibiting growth of certain tumors are also provided. Further, this application concerns a method for modulating class I histocompatibility antigens with MIS and EGF.
REFERENCES:
patent: 4289690 (1981-09-01), Pestka et al.
patent: 4404188 (1983-09-01), Donahoe et al.
patent: 4487833 (1984-12-01), Donahoe et al.
patent: 4510131 (1985-04-01), Donahoe et al.
patent: 4753794 (1988-06-01), Donahoe
patent: 4760156 (1988-07-01), Heffernan et al.
patent: 4792601 (1988-12-01), Donahoe et al.
patent: 4889724 (1989-12-01), Kasan et al.
patent: 5010055 (1991-04-01), Donahoe
patent: 5011687 (1991-04-01), Donahoe et al.
patent: 5047336 (1991-09-01), Cate et al.
patent: 5198420 (1993-03-01), Donahoe et al.
Cate et al., Cold Spring Harbor Symp. Quant. Biol. LI:641-647, (1986).
Fuller et al; Gynecol. Oncol. 17:124-132 (1984).
Wilson et al., Mol. Endocrinol. 7:247-257 (1993).
Hird et al. 1990. Sever and Cancer, Charney et al. (Ed.), John Wiley & Sons Ltd., N.Y., pp. 184-189.
Sofer et al. 1983. Bio Techniques, Nov./Dec., pp. 198-203.
Alexander et al., Adoptively Transferred Tumor-Infiltrating Lymphocytes Can Cure Established Metastatic Tumor in Mice and Persist Long-Term In Vivo as Funtional Memory T . . . , J. Immunol. 10:389-397 (1991).
Armstrong et al., Prolonged Survival Of Actively Enhanced Rat Renal Allografts Despite Accelerated Cellular Infiltration And Rapid Induction Of Both Class I and Class . . . , J. Exp. Med. 164:891-907 (1987).
Blaese et al., Retroviral-Mediated Gene Transfer Into Human Tumor-Infiltrating Lymphocytes (TIL): The First Authorized Protocol For The Use Of Gene Transfer In Man, Clinical Research 37(2):599A (1989).
Cate et al., Mullerian-Inhibiting Substance, in Handbook of Experimental Pharmacology 95/II:179-210 (1990).
Cate et al., Isolation of the Bovine and Human Genes for Mullerian Inhibiting Substance and Expression of the Human Gene in Animal Cells, Cells 45:685-698 (1986).
Chin et al., Human Mullerian Inhibiting Substance Inhibits Tumor Growth in Vitro and in Vivo, Cancer Research 51:2101-2106 (1991).
Culver et al., Lymphocytes as cellular vehicles for gene therapy in mouse and man, Proc. Natl. Acad. Sci USA 88:3155-3159 (1991).
Culver et al., In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors, Science 256:1550-1552 (1992).
Donahoe, P., Mullerian Inhibiting Substance: A Tyrosine Kinase Inhibitor With Anticancer Effects, J. Cellular Biochemistry 12A(Supp.):183 (1988).
Donahoe et al., Mullerian Inhibiting Substance Inhibits Growth of a Human Ovarian Cancer in Nude Mice, Ann. Surg. pp. 472-480 (Oct. 1981).
Donahoe et al., Mullerian Duct Regression in the Embryo Correlated with Cytotoxic Activity Against Human Ovarian Cancer, Science 205:913-915 (1979).
Eisenbach et al, MHC genes and oncogenes controlling the metastatic phenotype of tumor cells, Cancer Res. 5:1-18 (1986).
Feldman et al., What Makes a Tumor Cell Metastatic?, Scientific American Nov.:60-65, 68 and 85 (1988).
Fuller et al., Mullerian Inhibiting Substance Inhibits Colony Growth of a Human Ovarian Carcinoma Cell Line, Journal of Clinical Endocrinology and Metabolism 54(5):1051-1055 (1982).
Fuller et al., Mullerian Inhibiting Substance Reduction of Colony Growth of Human Gynecologic Cancers in a Stem Cell Assay, Gynecologic Oncology 22:135-148 (1985).
Fundenburg et al., (Eds.), Basic and Clinical Immunopathology 41:305-313 (1986).
Hudson et al., Mullerian Inhibiting Substance (MIS) Slows The Cell Cycle Progression of Human Epidermoid Carcinoma A431 Cells, J. Cell Biol. 115(3):176a Abstract No. 1599 (1991).
Hudson et al., Mullerian Inhibiting Substance (MIS) Slows The Cell Cycle Progression Human Epidermoid Carcinoma A431 Cells, J. Cell Biochem. Supp. 16B:123 Abstract No. G 112 (1992).
Hudson et al., An Immunoassay to Detect Human Mullerian Inhibiting Substance in Males and Females during Normal Development, J. Clin. Endocrin. and Metab. 70(1):16-22 (1990).
Kasid et al., Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man, Proc. Natl. Acad. Sci. USA 87:473-477 (1990).
MacLaughlin et al., Mullerian Duct Regression and Antiproliferative Bioactivities of Mullerian Inhibiting Substance Reside in it Carboxy-Terminal Domain, Endocrinology 131:291-296 (1992).
Miller et al., Redesign of Retrovirus Packaging Cell Lines To Avoid Recombination Leading to Helper Virus Production, Molecular and Cellular Biology 6(8):2895-2902 (1986).
Moolten et al., Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors, J. Natl. Cancer Institute 82:297-300 (1990).
Mullen et al., Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system, PNAS USA 89:33-37 (1992).
Ozato et al., Mouse major histocompatibility class I gene expression begins at midsomite stage and is inducible in earlier-stage embryos by interferon, Proc. Natl. Acad. Sci. USA 82:2427-2431 (1985).
Parry et al., Recombinant Human Mullerian Inhibiting Substance Inhibits Human Ocular Melonoma Cell Lines in Vitro and in Vivo, Cancer Research 52:1182-1186 (1992).
Pepinsky et al., Proteolytic Processing of Mullerian Inhibiting Substance Produces a Transforming Growth Factor-.beta.-like Fragment, J. Biol. Chem. 263(35):18961-18964 (1988).
Ragin et al., Human Mullerian Inhibiting Substance: Enhanced Purification Imparts Biochemical Stability and Restores Antiproliferative Effects, Protein Expression and Purification 3:236-245 (1992).
Ram et al., In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats, Cancer Research 53:83-88 (1993).
Rosenberg et al, A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes, Science 233:1318-1321 (1986).
Rosenberg et al., Use Of Tumor-Infiltrating Lymphocytes And Interleukin-2 In The Immunotherapy of Patients With Metastatic Melanoma, N. Eng. J. Med. 319:1676-1680 (1988).
H. Schreiber, in Fundamental Immunology, W.F. Paul, Ed., pp. 923, 939-943 (1989).
Speiss et al, In Vivo Antitumor Activity of Tumor-Infiltrating Lymphocytes Expanded in Recombinant Interleukin-2, J. Natl. Cancer Institute 79(5):1067-1075 (1987).
Tanaka et al, Reversal of Oncogenesis by the Expression of a Major Histocompatability Complex Class I Gene, Science 288:26-30 (1985).
Wallen et al., Minimal Antiproliferative Effect of Recombinant Mullerian Inhibiting Substance on Gynecological Tumor Cell Lines and Tumor Explants, Cancer Research 49:2005-2011 (1989).
Ziegler et al, Hypothesis: AIDS Is an Autoimmune Disease Directed at the Immume System and Triggered by a Lymphotropic Retrovirus, Clin. Immunology and Immunopathology 41:305-313 (1986).
Barksdale Edward M.
Chin Tai Wai
Donahoe Patricia K.
Epstein James
MacLaughlin David T.
Grimes Eric
The General Hospital Corporation
Wax Robert A.
LandOfFree
Use of mullerian inhibiting substance for treating certain tumor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of mullerian inhibiting substance for treating certain tumor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of mullerian inhibiting substance for treating certain tumor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1988569